ANAPTYSBIO, INC (ANAB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-27

Key Insights

AnaptysBio, Inc. announced the approval by its board of directors to distribute all outstanding shares of First Tracks Biotherapeutics, Inc. (SpinCo) to AnaptysBio shareholders as a pro rata dividend.
First Tracks Biotherapeutics has entered into a purchase agreement to issue and sell 5,791,478 shares of its common stock for approximately $80 million in gross proceeds, as well as 4,705,576 secondary shares from a selling stockholder.
The private placement of First Tracks Biotherapeutics shares is expected to close immediately after the spin-off from AnaptysBio, which is planned for April 20, 2026.

Want the newest filings?

This analysis covers the filing from 2026-03-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-09

AnaptysBio expects to report approximately $310 million in cash and cash equivalents as of December 31, 2025, indicating a strong financial position.
The company plans to provide preliminary, unaudited financial information in an upcoming presentation, though the final audited results may differ.
Investors should watch for the full audited financial statements to be released, as the preliminary information may not provide a complete picture of the company's performance.

Other reports for ANAPTYSBIO, INC

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.